Regulatory Compliance: Why Paper Programs Fail Enforcement Review

A compliance officer who reports to the general counsel, who reports to the CEO, who approves the compliance budget is structurally compromised before the first investigation opens.

DOJ's 2023 guidance specifically asks whether the compliance function has sufficient autonomy from management, sufficient resources relative to the company's risk profile, and sufficient access to senior leadership and the board to escalate concerns without business-unit filtering. A compliance officer with direct board access who can escalate findings to the audit committee, whose budget is set independently of the business units the function oversees, and whose investigative findings are acted upon satisfies the structural independence test. A compliance function embedded within a business unit whose revenues it is expected to protect does not.

The compliance officer's qualifications matter separately. DOJ asks whether the compliance function is staffed by people with expertise to identify the specific risks the company faces. A financial services compliance officer without securities law experience, a healthcare compliance function staffed entirely by former billing personnel with no fraud and abuse background, and a manufacturing compliance team without environmental regulatory expertise each signal that the company allocated headcount to satisfy an organizational chart requirement rather than to address actual risk. Structural independence and subject matter expertise together determine what regulators find when they evaluate whether the program was genuinely implemented or maintained as a formality.

A company is not insulated from its vendor's regulatory failures simply because the vendor, not the company, committed the violation.

FCPA enforcement makes this explicit: a company that paid a foreign government official through a third-party distributor, consultant, or joint venture partner has violated the FCPA regardless of whether the company knew the specific payment was made, if it failed to conduct adequate due diligence, failed to include compliance protections in the third-party agreement, and failed to audit the relationship for compliance. DOJ and SEC have pursued enforcement actions against companies whose third-party agents bribed officials with funds the company provided as commissions or consulting fees without any reasonable basis for believing those funds would be used legitimately. The standard requires actual diligence proportionate to the relationship's risk profile, not a signature on a compliance questionnaire. FCPA compliance and export compliance law programs must specifically address third-party due diligence, contractual compliance representations, and ongoing monitoring for each high-risk vendor relationship.

Healthcare and government contracting present parallel third-party risk. A hospital that engaged a physician practice management company that submitted false claims using the hospital's provider number has created False Claims Act liability at the hospital level regardless of whether the hospital reviewed the claims before submission. A government contractor whose subcontractor falsified testing results on components the prime contractor certified as compliant has created exposure that the prime contractor's own certification makes unavoidable. The compliance program's third-party component must address due diligence at engagement, contractual flow-down requirements, and monitoring throughout the relationship, not only at the initial contracting stage.

FDA regulatory compliance for medical device manufacturers and pharmaceutical companies illustrates how the cost of a non-functioning compliance program compounds across multiple enforcement mechanisms simultaneously. A manufacturer with inadequate quality management systems faces FDA Form 483 observations, warning letters, consent decrees requiring independent expert supervision of manufacturing operations, import alerts blocking products from U.S. .ntry, and potential criminal referral when adulteration is knowing. Each mechanism operates independently: a consent decree does not preclude criminal prosecution, and an import alert does not require a prior warning letter. FDA regulatory compliance programs that satisfy the current Good Manufacturing Practice standards at 21 C.F.R. Parts 211 and 820 prevent this cascade; programs that treat GMP documentation as a paperwork exercise produce it.

A compliance program designed around U.S. .egulatory requirements may be entirely inadequate for a company that operates in, sells into, or sources from international markets.

GDPR Article 24 imposes accountability obligations on data controllers that go beyond what most U.S. .tate privacy laws require, including data protection impact assessments for high-risk processing activities, records of processing activities, and data protection by design requirements that must be built into systems at development rather than added as controls afterward. A U.S. .ompany that processes EU personal data, sells products in the EU market, or has EU-based employees and has not evaluated its compliance program against GDPR's accountability framework has created enforcement exposure with EU supervisory authorities that runs parallel to and independently of any U.S. .rivacy law obligation. GDPR fines can reach four percent of global annual revenue for the most serious violations, a penalty scale that dwarfs most U.S. .ivil penalty structures for companies operating at significant revenue levels.

The UK Bribery Act's Section 7 offense creates corporate criminal liability for failing to prevent bribery by any person associated with the organization, subject only to the defense that the organization had adequate procedures in place to prevent bribery. A company with operations or sales in the UK that relies solely on its FCPA compliance program without evaluating whether that program satisfies the UK Bribery Act's adequate procedures standard has left a jurisdiction-specific defense unbuilt. EU regulatory compliance and data privacy compliance obligations require program design that addresses both frameworks simultaneously, because EU regulators do not accept U.S.-centric programs as adequate compliance with EU accountability requirements.

DOJ's 2023 Evaluation of Corporate Compliance Programs asks three questions: whether the program is well-designed based on an actual risk assessment of the company's specific operations; whether it is resourced and implemented in good faith, including compliance officer independence and board access; and whether it worked in practice at the time of the offense. A program that answers all three questions with documented evidence produces a materially different enforcement outcome than one that can only produce a policy binder. The program's design must reflect the company's specific risk profile, and its monitoring and audit functions must generate evidence that the program detected or attempted to detect violations before the government did.

Healthcare faces the most severe per-violation penalty structure through the False Claims Act, which imposes triple damages plus per-claim penalties adjusted annually for inflation. Environmental violations under the Clean Air Act accrue civil penalties adjusted annually, reaching over $70,000 per day per violation as of recent adjustments, producing substantial settlement demands when violations continue unreported for extended periods. Financial services violations combining disgorgement, penalties, and prejudgment interest have produced multi-billion-dollar SEC settlements. The penalty structure in any industry is the baseline for understanding what an adequate compliance investment must be designed to prevent, and compliance audits calibrated to those penalty levels are the minimum required to evaluate whether the program's scope matches the risk.

DOJ and SEC both provide significant credit for companies whose programs identified and reported violations before regulators discovered them, who remediated promptly, and who cooperated fully. The U.S. Sentencing Guidelines for organizational defendants allow substantial downward adjustments from the base fine for companies with effective programs that self-reported and cooperated. The difference between maximum available mitigation and no mitigation can represent hundreds of millions of dollars in large enforcement matters. A company whose program was genuine and well-documented starts every enforcement negotiation from a materially better position than one that cannot demonstrate that it tried to prevent and detect the violation before it was caught.

Third-party compliance components must address due diligence conducted before engagement, proportionate to the risk of the specific relationship; contractual compliance representations, warranties, and audit rights; and ongoing monitoring of high-risk vendor relationships after engagement begins. FCPA enforcement has established that written certifications from third parties are insufficient without a reasonable basis for believing those certifications are accurate, which requires actual diligence rather than a signature on a compliance questionnaire. Government regulatory compliance and federal program compliance programs must specifically address third-party risk categories most prevalent in the company's business model, because False Claims Act and FCPA enforcement both treat inadequate vendor oversight as a direct corporate compliance failure.